U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23ClN2O2
Molecular Weight 382.884
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORATADINE

SMILES

CCOC(=O)N1CCC(=C2c3ccc(cc3CCc4cccnc42)Cl)CC1

InChI

InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H23ClN2O2
Molecular Weight 382.884
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Curator's Comment:: The second generation antihistamines were less soluble in lipid and thus less readily penetrated the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLARITIN

Approved Use

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat

Launch Date

7.3457277E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.1 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.8 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
96 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
34.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.4 h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Other AEs: Somnolence, Headache...
Other AEs:
Somnolence (10%)
Headache (9%)
Fatigue (5%)
Dry mouth (4%)
Sources:
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Other AEs: Fatigue, Fever...
Other AEs:
Fatigue (2%)
Fever (7%)
Headache (5%)
Influenza-like symptoms (2%)
Constipation (2%)
Diarrhea (3%)
Dyspepsia (2%)
Loose stools (2%)
Stomatitis (2%)
Tooth disorder (2%)
Vomiting (5%)
Earache (2%)
Drowsiness (7%)
Infection viral (2%)
Allergic rhinitis (2%)
Coughing (3%)
Epistaxis (3%)
Pharyngitis (3%)
Rash (2%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
n = 331
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 35.3
Sex: M+F
Population Size: 331
Sources:
Other AEs: Headache...
Other AEs:
Headache (4.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Somnolence 10%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Dry mouth 4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Fatigue 5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Allergic rhinitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Constipation 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Dyspepsia 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Earache 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Fatigue 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Infection viral 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Influenza-like symptoms 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Loose stools 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Rash 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Stomatitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Tooth disorder 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Coughing 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Diarrhea 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Epistaxis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Pharyngitis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Headache 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Vomiting 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Drowsiness 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Fever 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Headache 4.2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
n = 331
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 35.3
Sex: M+F
Population Size: 331
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
minor
minor
minor
minor
minor
minor
minor
minor
yes (co-administration study)
Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
2001
Treatment of urticaria. An evidence-based evaluation of antihistamines.
2001
[Effect of loratadine in children with allergic rhinitis].
2001 Aug 26
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system.
2001 Dec
QTc prolongation and drugs.
2001 Dec
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
2001 Jul-Aug
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
2001 Nov
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs).
2001 Nov 1
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.
2001 Nov 1
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.
2001 Nov 26
[Approaches to prevention and treatment of latex allergy].
2001 Nov-Dec
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.
2001 Oct
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
2001 Oct
A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years.
2001 Sep
Controlled clinical study of the efficacy of loratadine in Nigerian patients with allergic rhinitis.
2001 Sep
Do antihistamines impair school performance in children?
2001 Sep
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.
2001 Sep
[Comparative antihistamine and anti-allergic effects of various antihistamine preparations].
2002
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
2002
Clinical evidence for antileukotriene therapy in the management of allergic rhinitis.
2002 Apr
Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests.
2002 Apr
Are antihistamines useful in managing asthma?
2002 Feb
[Clinical evaluation of the ocular safety of Amukine 0.06% solution for local application versus povidone iodine (Bétadine) 5% solution for ocular irrigation) in preoperative antisepsis].
2002 Feb
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
2002 Feb
Medical management of Cronkhite-Canada syndrome.
2002 Feb
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).
2002 Feb
Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart.
2002 Feb
[The third-generation antihistaminics. Can they prevent the tier change?].
2002 Feb 14
Cardiotoxicity of new antihistamines and cisapride.
2002 Feb 28
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.
2002 Jan
The effect of loratadine in exercise-induced asthma.
2002 Jan
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
2002 Jan 1
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
2002 Jun
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
2002 Jun
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
2002 Jun
Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
2002 Jun
Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma.
2002 Jun 15
Stability indicating methods for the determination of loratadine in the presence of its degradation product.
2002 Jun 15
LC determination of loratadine and related impurities.
2002 Jun 20
Which is more effective for as-needed treatment of seasonal allergy symptoms: intranasal corticosteroids or oral antihistamines?
2002 Mar
Fixed drug eruption due to loratadine.
2002 Mar
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
2002 Mar
Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
2002 Mar
Desloratadine (Clarinex).
2002 Mar 18
Med-psych drug-drug interactions update.
2002 Mar-Apr
Loratadine/nefazodone interaction.
2002 May
Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction.
2002 May
Exercise-induced asthma: is there still a case for histamine?
2002 May
The cost of treating allergic rhinitis.
2002 May
Ventricular tachycardia following ingestion of a commonly used antihistamine.
2002 May 6
Patents

Sample Use Guides

Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration: Oral
In Vitro Use Guide
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:55 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:55 UTC 2021
Record UNII
7AJO3BO7QN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LORATADINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
SCH-29851
Code English
1-PIPERIDINECARBOXYLIC ACID, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-, ETHYL ESTER
Common Name English
LORATADINE [MART.]
Common Name English
LORATADINE [USP MONOGRAPH]
Common Name English
LORATADINE [EP MONOGRAPH]
Common Name English
LORATADINE [HSDB]
Common Name English
LORATADINE [WHO-DD]
Common Name English
LORATADINE [MI]
Common Name English
LORATADINE COMPONENT OF CLARITIN-D
Common Name English
BAY76-2211
Code English
LORATADINE [USP-RS]
Common Name English
SCH 29851
Code English
LORATADINE [USAN]
Common Name English
LORATADINE [EP]
Common Name English
ALAVERT
Brand Name English
CLARITIN-D COMPONENT LORATADINE
Common Name English
LORATADINE [INN]
Common Name English
NSC-758628
Code English
LORATADINE [ORANGE BOOK]
Common Name English
LORATADINE [VANDF]
Common Name English
LORATADINE [JAN]
Common Name English
CLARITIN
Brand Name English
ETHYL 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLATE
Systematic Name English
Classification Tree Code System Code
WHO-ATC R06AX13
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
WHO-VATC QR06AX13
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
LIVERTOX 570
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
Code System Code Type Description
EPA CompTox
79794-75-5
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
IUPHAR
7216
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
USP_CATALOG
1370270
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY USP-RS
INN
5864
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
CAS
79794-75-5
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
PUBCHEM
3957
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
MERCK INDEX
M6905
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1605
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
MESH
D017336
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
LACTMED
Loratadine
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
FDA UNII
7AJO3BO7QN
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
EVMPD
SUB08581MIG
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
HSDB
3578
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
RXCUI
28889
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL998
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
DRUG BANK
DB00455
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
WIKIPEDIA
LORATADINE
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
NCI_THESAURUS
C29162
Created by admin on Fri Jun 25 21:00:55 UTC 2021 , Edited by admin on Fri Jun 25 21:00:55 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
METABOLIC ENZYME -> INHIBITOR
IC50
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT->INNOVATOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC